PMID- 36866734
OWN - NLM
STAT- MEDLINE
DCOM- 20230331
LR  - 20230414
IS  - 1531-6971 (Electronic)
IS  - 1070-5287 (Linking)
VI  - 29
IP  - 3
DP  - 2023 May 1
TI  - Eosinophilic respiratory disorders and the impact of biologics.
PG  - 202-208
LID - 10.1097/MCP.0000000000000951 [doi]
AB  - PURPOSE OF REVIEW: Eosinophils are involved in combating parasitic, bacterial, 
      viral infections as well as certain malignancies. However, they are also 
      implicated in an array of upper and lower respiratory disease states. Through a 
      deeper understanding of disease pathogenesis, targeted biologic therapies have 
      revolutionized glucocorticoid sparing treatment of eosinophilic respiratory 
      diseases. This review will focus on the impact of novel biologics on the 
      management of asthma, eosinophilic granulomatosis with polyangiitis, allergic 
      bronchopulmonary aspergillosis (ABPA), hypereosinophilic syndrome (HES) and 
      chronic rhinosinusitis with nasal polyposis (CRSwNP). RECENT FINDINGS: Key 
      immunologic pathways affecting Type 2 inflammation through immunoglobulin E 
      (IgE), interleukin (IL-4), IL-5, IL-13, and upstream alarmins such as thymic 
      stromal lymphopoietin (TSLP), have led to novel drug developments. We explore the 
      mechanism of action for Omalizumab, Mepolizumab, Benralizumab, Reslizumab, 
      Dupilumab, and Tezepelumab, their respective Food and Drug Administration (FDA) 
      indications, and biomarkers affecting treatment decisions. We also highlight 
      investigational therapeutics that are likely to impact the future management of 
      eosinophilic respiratory diseases. SUMMARY: Insight into the biology of 
      eosinophilic respiratory diseases has been critical for understanding disease 
      pathogenesis and has contributed to the development of effective 
      eosinophil-targeted biologic interventions.
CI  - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Bernstein, Joshua S
AU  - Bernstein JS
AD  - National Jewish Health, Denver, Colorado, USA.
FAU - Wechsler, Michael E
AU  - Wechsler ME
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230303
PL  - United States
TA  - Curr Opin Pulm Med
JT  - Current opinion in pulmonary medicine
JID - 9503765
RN  - 2P471X1Z11 (Omalizumab)
RN  - 0 (Biological Products)
SB  - IM
MH  - Humans
MH  - *Churg-Strauss Syndrome/drug therapy
MH  - *Granulomatosis with Polyangiitis/drug therapy
MH  - *Asthma/drug therapy
MH  - Omalizumab/therapeutic use
MH  - *Biological Products/therapeutic use
EDAT- 2023/03/04 06:00
MHDA- 2023/03/31 06:41
CRDT- 2023/03/03 05:53
PHST- 2023/03/31 06:41 [medline]
PHST- 2023/03/04 06:00 [pubmed]
PHST- 2023/03/03 05:53 [entrez]
AID - 00063198-202305000-00012 [pii]
AID - 10.1097/MCP.0000000000000951 [doi]
PST - ppublish
SO  - Curr Opin Pulm Med. 2023 May 1;29(3):202-208. doi: 10.1097/MCP.0000000000000951. 
      Epub 2023 Mar 3.